Maraviroc: A Coreceptor CCR5 Antagonist for Management of HIV Infection

Raymond Yost; Timothy R. Pasquale; Eric G. Sahloff

Disclosures

Am J Health Syst Pharm. 2009;66(8):715-726. 

In This Article

Dosage and Administration

Maraviroc is formulated in 150- and 300-mg tablets, with standard dosing of 300 mg orally twice daily.[2] Concomitant use of maraviroc with known CYP3A inhibitors (including but not limited to ketoconazole, itraconazole, clarithromycin, PIs [except tipranavir], and telithromycin) necessitates that the maraviroc dosage be reduced to 150 mg twice daily. When given with known CYP3A inducers (including but not limited to efavirenz, rifampin, carbamazepine, phenobarbital, and phenytoin), the maraviroc dosage should be increased to 600 mg twice daily.

Maraviroc has not been evaluated in patients with renal or hepatic dysfunction. Approximately 25% of total maraviroc clearance occurs via the kidneys. Maraviroc should be used cautiously in patients with a creatinine clearance of < 50 mL/min, especially when used concurrently with a CYP3A inhibitor, as maraviroc may accumulate, leading to potential maraviroc-related toxicities.[2] Maraviroc should also be used cautiously in patients with hepatic in-sufficiency. Hepatic injury could limit the metabolism of maraviroc, leading to increased maraviroc concentrations and potential adverse effects.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....